Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase 3 Clinical |
The First Affiliated Hospital Of Soochow University |
Leukemia; Multiple Myeloma |
Details
|
Anitocabtagene autoleucel |
CART-ddBCMA; Kite-772 |
Phase 3 Clinical |
Arcellx Inc |
Myasthenia Gravis; Neuromuscular Manifestations; Autoimmune Diseases; Multiple Myeloma; Muscular Diseases; Muscle Weakness; Autoimmune Diseases of the Nervous System |
Details
|
CD3 and B-cell maturation antigen T-cell engaging bispecific antibody (AbbVie/TeneoOne) |
ABBV-383; TNB-383B |
Phase 3 Clinical |
TeneoOne Inc |
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma |
Details
|
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) |
Descartes-08 |
Phase 3 Clinical |
Cartesian Therapeutics Inc |
Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
BCMA CAR-T Cells (Pregene) |
PRG-1801; GLPG-5301; DRL-1801 |
Phase 2 Clinical |
|
Purpura, Thrombocytopenic, Idiopathic; Immunoglobulin G4-Related Disease; Multiple Myeloma; Lupus Nephritis |
Details
|
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) |
BCMA-CART; HR003 |
Phase 2 Clinical |
Hrain Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Lymphoma, B-Cell; Multiple Myeloma; Lymphoma, Non-Hodgkin |
Details
|
BCMA CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell |
Details
|
C-CAR088 |
C-CAR088 |
Phase 2 Clinical |
Cellular Biomedicine (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|
Orvacabtagene autoleucel |
ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 |
Phase 2 Clinical |
Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc |
Multiple Myeloma |
Details
|
GC-012F |
GC-012F; GC012F; AZD-0120; AZD0120 |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
KQ-2003 |
KQ2003; KQ-2003 |
Phase 2 Clinical |
Shanghai Keqi Pharmaceutical Technology Co Ltd |
Solid tumours; Multiple Myeloma; POEMS Syndrome |
Details
|
HDP-101 |
HDP-101; HDP101-ATAC |
Phase 2 Clinical |
Heidelberg |
Hematologic Diseases; Paraproteinemias; Multiple Myeloma |
Details
|
REGN-5459 |
REGN-5459 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Multiple Myeloma; Renal Insufficiency, Chronic |
Details
|
BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital) |
|
Phase 2 Clinical |
Peking University People'S Hospital |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Immunoglobulin G4-Related Disease; Sjogren's Syndrome; Scleroderma, Systemic; Antiphospholipid Syndrome; Lupus Erythematosus, Systemic; Acquired thrombotic thrombocytopenic purpura; Behcet Syndrome |
Details
|
anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University) |
|
Phase 2 Clinical |
Xuzhou Medical University (Xzmu) |
Multiple Myeloma |
Details
|
BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Multiple Myeloma |
Details
|
Chimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Xiamen University |
Hematologic Neoplasms; Multiple Myeloma |
Details
|
BCD-248 |
BCD-248 |
Phase 2 Clinical |
BIOCAD JSC |
Multiple Myeloma |
Details
|
Nanobody-based biepitope BCMA-targeting CAR-T cells therapy(Tahoe Chunyu Biotechnology) |
|
Phase 2 Clinical |
Hebei Tahoe Chunyu Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health |
Plasmacytoma; Multiple Myeloma |
Details
|
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech) |
|
Phase 2 Clinical |
Essen Biotech |
Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Microscopic Polyangiitis; Myositis; Scleroderma, Systemic; Autoimmune Diseases; Sjogren's Syndrome; Lupus Nephritis; Lupus Erythematosus, Systemic |
Details
|
Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences) |
|
Phase 2 Clinical |
Shahid Beheshti University Of Medical Sciences |
Multiple Myeloma |
Details
|
IBI-3003 |
IBI3003; IBI-3003 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene) |
|
Phase 2 Clinical |
Guangzhou Bio-Gene Technology Co Ltd |
Multiple Myeloma |
Details
|
CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital) |
|
Phase 2 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Multiple Myeloma |
Details
|
MBS-314 |
MBS-314 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Multiple Myeloma |
Details
|
SAR445514 |
SAR445514; SAR-445514; IPH6401/SAR514 |
Phase 2 Clinical |
Sanofi |
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma |
Details
|
CART-BCMA(Simnova) |
SNC-102(Simnova); SNC102(Simnova) |
Phase 2 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Shanghai YaKe Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
CAR-BCMA(Sheba Medical Center) |
|
Phase 2 Clinical |
Sheba Medical Center, Israel |
Multiple Myeloma |
Details
|
Humanized CART Directed Against BCMA |
ARI-0002h |
Phase 2 Clinical |
Instituto De Salud Carlos Iii |
Multiple Myeloma |
Details
|
Descartes-11 |
Descartes-11; Descartes-011 |
Phase 2 Clinical |
Cartesian Therapeutics Inc |
Multiple Myeloma |
Details
|
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Multiple Myeloma |
Details
|
GR-1803 |
GR-1803 |
Phase 2 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
CM-336(Connaught Biomedical Technology) |
CM-336; OM336 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Multiple Myeloma |
Details
|
PHE-885 |
PHE-885 |
Phase 2 Clinical |
Novartis Pharma Ag |
Hematologic Neoplasms; Multiple Myeloma |
Details
|
EMB-06 |
EMB-06; EMB06; CN106; CND106; CND-106 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Multiple Myeloma; Pemphigus |
Details
|
NXC-201 |
HBI-0101; NXC-201 |
Phase 2 Clinical |
Immix Biopharma Inc, Hadassah Medical Organization |
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma |
Details
|
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Neoplasms; Multiple Myeloma |
Details
|
BCMA TriTAC |
HPN-217 |
Phase 1 Clinical |
Harpoon Therapeutics, Abbvie Inc |
Multiple Myeloma |
Details
|
ACTR 087/SEA BCMA combination therapy |
|
Phase 1 Clinical |
Unum Therapeutics Inc |
Multiple Myeloma |
Details
|
bb-21217 |
bb-21217 |
Phase 1 Clinical |
Bluebird Bio Inc, Bristol-Myers Squibb Company |
Multiple Myeloma |
Details
|
AMG-224 |
AMG-224 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
Ispectamab debotansine |
CC-99712; BMS-986352; SP-8919 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
Pacanalotamab |
AMG-420; BI-836909 |
Phase 1 Clinical |
Micromet Inc |
Multiple Myeloma |
Details
|
ALLO-715 |
ALLO-715 |
Phase 1 Clinical |
Cellectis Sa |
Multiple Myeloma |
Details
|
Alnuctamab |
CC-93269; EM-901; BMS-986349 |
Phase 1 Clinical |
Engmab Ag |
Multiple Myeloma |
Details
|
Pavurutamab |
AMG-701 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
CART-BCMA |
MTV-273; CART-BCMA |
Phase 1 Clinical |
University Of Pennsylvania |
Rejection of renal transplantation; Renal Insufficiency; Multiple Myeloma; Kidney Failure, Chronic |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Multiple Myeloma; Lupus Erythematosus, Systemic; Pancytopenia; Waldenstrom Macroglobulinemia |
Details
|
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase 1 Clinical |
Shengyan Pharmaceutical Technology |
Multiple Myeloma |
Details
|
Descartes-15 |
Descartes-015; Descartes-15 |
Phase 1 Clinical |
Cartesian Therapeutics Inc |
Solid tumours; Multiple Myeloma; Autoimmune Diseases of the Nervous System |
Details
|
ACLX-001 |
ACLX-001 |
Phase 1 Clinical |
Arcellx Inc |
Multiple Myeloma |
Details
|
CB-011 |
CB-011 |
Phase 1 Clinical |
Caribou Biosciences Inc |
Multiple Myeloma |
Details
|
FT-576 |
FT-576 |
Phase 1 Clinical |
University Of Minnesota, Fate Therapeutics Inc |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
P-BCMA-ALLO1 |
P-BCMA-ALLO1; RG-6538 |
Phase 1 Clinical |
Janssen Biotech Inc, Transposagen Biopharmaceuticals Inc |
Multiple Myeloma |
Details
|
Anti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine) |
KN5601; KN-5601 |
Phase 1 Clinical |
The Children'S Hospital, Zhejiang University School Of Medicine |
Nephrosis; Autoimmune Diseases; Lupus Erythematosus, Systemic |
Details
|
RD06-05 CART Cell Therapy(Nanjing Bioheng Biotech) |
RD06-05 |
Phase 1 Clinical |
Nanjing Bioheng Biotech Co Ltd |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica; Lupus Erythematosus, Systemic |
Details
|
Universal allogeneic anti-CD19/BCMA CAR T-cells therapy(XiNiao Biotechnology) |
|
Phase 1 Clinical |
Hangzhou XiNiao Biotechnology Co Ltd |
Anemia, Hemolytic, Autoimmune |
Details
|
68Ga-BC1 |
68Ga-BC1 |
Phase 1 Clinical |
The First Affiliated Hospital Of Beijing University |
Multiple Myeloma; Neoplasms, Plasma Cell |
Details
|
ESO-T01 |
ESO-T01 |
Phase 1 Clinical |
Shenzhen Pregene Biopharma Co Ltd |
Multiple Myeloma |
Details
|
Universal BCMA-Targeted CAR-T Therapy(Wondercel) |
REVO-UWD-00B |
Phase 1 Clinical |
Wondercel Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine) |
|
Phase 1 Clinical |
The Children'S Hospital, Zhejiang University School Of Medicine |
Nephrosis |
Details
|
PRG-2311 |
PRG-2311 |
Phase 1 Clinical |
|
Immunoglobulin G4-Related Disease; Lupus Nephritis |
Details
|
BZE-2204 |
BZE2204; BZE-2204 |
Phase 1 Clinical |
Shanghai Cell Therapy Group Co Ltd |
Lymphoma, B-Cell; Multiple Myeloma |
Details
|
OL-101 |
OL-101 |
Phase 1 Clinical |
Overland Pharmaceuticals (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|
Anti-CD19/BCMA CAR T-cell therapy(YaKe Biotechnology) |
|
Phase 1 Clinical |
Shanghai YaKe Biotechnology Co Ltd, Zhejiang University |
Lupus Nephritis; Lupus Erythematosus, Systemic |
Details
|
Zirconium-89 belantamab |
89Zr-GSK2857914 |
Phase 1 Clinical |
Glaxosmithkline Plc |
Neoplasms; Multiple Myeloma |
Details
|
RD-140 |
RD140 |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Leukemia, Plasma Cell; Multiple Myeloma |
Details
|
BCMA CAR-NK (Hrain Biotechnology) |
HR012 |
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Leukemia, Plasma Cell; Multiple Myeloma |
Details
|
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital) |
|
Phase 1 Clinical |
Wuhan Union Hospital |
Lupus Erythematosus, Systemic |
Details
|
SYS-6020 |
SYS6020; SYS-6020 |
Phase 1 Clinical |
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd |
Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine) |
FKC-288; FKC288 |
Phase 1 Clinical |
Nanjing University School Of Medicine |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Immunoglobulin G4-Related Disease; Lupus Nephritis |
Details
|
YKST-02 |
YKST02; YKST-02 |
Phase 1 Clinical |
Excyte Biopharma Ltd |
Multiple Myeloma |
Details
|
C-CAR168 CAR T-cell therapy (AbelZeta) |
C-CAR168 |
Phase 1 Clinical |
Cellular Biomedicine (Shanghai) Co Ltd |
Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Lupus Erythematosus, Systemic; Neuromyelitis Optica; Muscular Diseases |
Details
|
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) |
BMS-986453 |
Phase 1 Clinical |
Juno Therapeutics Inc |
Multiple Myeloma |
Details
|
SIM-0500 |
SIM0500; SIM-0500 |
Phase 1 Clinical |
Simcere Pharmaceutical Group Ltd |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) |
|
Phase 1 Clinical |
Hualan Genetic Engineering (Henan) Co Ltd |
Multiple Myeloma |
Details
|
BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics) |
CBG-002 CAR-T |
Phase 1 Clinical |
Carbiogene Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma) |
SWK001; SWK-001 |
Phase 1 Clinical |
Hunan Siweikang Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T (Nanjing Kati Medical Technology) |
|
Phase 1 Clinical |
Nanjing Kati Medical Technology Co Ltd |
Multiple Myeloma |
Details
|
Belantamab |
GSK2857914; GSK-2857914 |
Phase 1 Clinical |
Glaxosmithkline Plc |
Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) |
|
Phase 1 Clinical |
Eugia Pharma Specialities Ltd, Actavis Inc |
Multiple Myeloma |
Details
|
LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co) |
|
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Universal BCMA-CD19 CART cell therapy(BRL Medicine) |
BRL-302 |
Phase 1 Clinical |
BRL Medicine Inc |
Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Solid tumours; Autoimmune Diseases; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Prostatic Neoplasms |
Details
|
TQB-2934 |
TQB2934; TQB-2934 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Multiple Myeloma |
Details
|
MCARH-125 |
MCARH-125 |
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Multiple Myeloma |
Details
|
ISB-2001 |
ISB-2001 |
Phase 1 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma |
Details
|
OriC-321 |
OriC-321; Ori-C-321 |
Phase 1 Clinical |
Zhejiang University, OriCell Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
HY-027 |
HY-027 |
Phase 1 Clinical |
Juventas Cell Therapy Ltd |
Multiple Myeloma |
Details
|
MEDI-2228 |
MEDI-2228 |
Phase 1 Clinical |
Medimmune Llc |
Multiple Myeloma |
Details
|
IBI-346 |
IBI-346 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA-NKE |
BCMA-NKE |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Multiple Myeloma |
Details
|
MCM-998 |
MCM-998; LXG-250 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
BCMA-UCART cell therapy (Shanghai Bioray Laboratory) |
|
Phase 1 Clinical |
BRL Medicine Inc |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis; Multiple Sclerosis; Multiple Myeloma; Neuromyelitis Optica |
Details
|
ALLO-605 |
ALLO-605; ALLO605 |
Phase 1 Clinical |
Cellectis Sa, Overland Pharmaceuticals (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|
AUTO-8 |
AUTO-8; AUTO8 |
Phase 1 Clinical |
Autolus Therapeutics Plc, University College London |
Multiple Myeloma |
Details
|
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) |
|
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Multiple Myeloma |
Details
|
JWCAR129 |
JWCAR129; JWCAR-129 |
Phase 1 Clinical |
Suzhou Yaomingjunuo Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) |
|
Phase 1 Clinical |
Chongqing Xinqiao Hospital |
Multiple Myeloma |
Details
|
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) |
LCAR-BCX |
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University, Shanghai YaKe Biotechnology Co Ltd |
Nephritis; Scleroderma, Systemic; Autoimmune Diseases; Sjogren's Syndrome; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
C-4-29 |
|
Phase 1 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Carcinoma, Renal Cell; Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
Multiple Myeloma |
Details
|
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Multiple Myeloma |
Details
|
CC-98633 |
CC-98633 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) |
|
Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Hematologic Neoplasms |
Details
|
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) |
|
Clinical |
Huazhong University Of Science And Technology |
Multiple Myeloma |
Details
|
SA-102 |
SA-102; SA102 |
Clinical |
Wuhan Si'an Medical Technology Co Ltd |
Multiple Myeloma |
Details
|
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics) |
ACT-001(Acellytron Therapeutics) |
Clinical |
Acellytron Therapeutics |
Multiple Myeloma |
Details
|
Anti-BCMA chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics) |
|
Clinical |
|
Multiple Myeloma |
Details
|
PD-1Ab21-BCMACAR-T (CD biopharma) |
CD-003; CD-203 |
Clinical |
|
Multiple Myeloma |
Details
|
BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics) |
UTAA17 |
Clinical |
Persongen Biotherapeutics (Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
CT-0590(The First Affiliated Hospital Of Soochow University) |
CT-0590 |
Clinical |
CARsgen Therapeutics Holdings Ltd |
Multiple Myeloma |
Details
|
UF-KURE-BCMA CAR-T Cells therapy(University Hospitals Cleveland Medical Center) |
|
|
University Hospitals Cleveland Medical Center |
|
Details
|